Breaking Finance News

SurModics, Inc. (NASDAQ:SRDX) has been downgraded to Neutral in a statement by Sidoti earlier today.

Having a price of $29.25, SurModics, Inc. (NASDAQ:SRDX) traded -3.91% lower on the day. With the last stock price up 19.59% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. SRDX has recorded a 50-day average of $29.02 and a two hundred day average of $24.44. Trade Volume was up over the average, with 84,887 shares of SRDX changing hands over the typical 56,765

Sidoti has downgraded SurModics, Inc. (NASDAQ:SRDX) to Neutral in a statement released on 10/06/2016.

On Tuesday May 03, 2016, Barrington Research released a statement about SurModics, Inc. (NASDAQ:SRDX) upped the target price from $27.00 to $30.00 that suggested an upside of 0.30%.

Recent Performance Chart

SurModics, Inc. (NASDAQ:SRDX)

SurModics, Inc. has PE ratio of 43.69 with a one year low of $17.45 and a one year high of $30.75 and has a market capitalization of $0.

A total of 4 brokerages have issued a ratings update on SurModics, Inc.. Three brokerages rating the company a strong buy, one brokerage rating the company a buy, zero brokerages rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $29.75.

General Company Details For SurModics, Inc. (NASDAQ:SRDX)

SurModics, Inc. is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company is focused on to transform its medical device business from being a provider of coating technologies to offering whole product solutions to medical device customers. The Company's Medical Device segment consists of surface modification coating technologies to improve access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device. The Company's In Vitro Diagnostics segment manufactures or sells components for in vitro diagnostic immunoassay and molecular tests. Its products include BioFX Liquid Nova-Stop Solution, StabilZyme Protein-Free AP Stabilizer, StabilZyme Protein-Free Stabilizer and StabilBlot Blocker Family.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *